Context No head-to-head clinical trials compare contemporary first-line therapies for
metastatic renal cell carcinoma (mRCC). A network meta-analysis provides an approach for …

Abstract Context The European Association of Urology Renal Cell Carcinoma (RCC)
Guideline Panel has prepared evidence-based guidelines and recommendations for the …

Kidney cancer accounts for 5% and 3% of all adult malignancies in men and women,
respectively, thus representing the 7th most common cancer in men, and the 10th most …

Purpose: Inflammation indexes and body mass index (BMI) are easily evaluated, predict
survival, and are potentially modifiable. We evaluated the potential association of …

Aim: Estimate prognosis and clinical outcome of patients with localized or metastatic renal
cell carcinoma (RCC) is an important issue which drive our medical decisions. Methods: We …

Background Nivolumab-ipilimumab demonstrated a survival benefit over sunitinib in first-line
setting for metastatic renal cell carcinomas (mRCCs) and is becoming a new standard of …

Objective To report the safety and efficacy results of patients enrolled in the Italian
Nivolumab Renal Cell Cancer Expanded Access Programme. Patients and Methods …

Background Predictive factors that can be routinely used in clinical practice are critically
needed for immune checkpoint inhibitor therapy in metastatic renal cell carcinoma (mRCC) …

PURPOSE Somatostatin analogs (SSAs) are recommended for the first-line treatment of
most patients with well-differentiated, gastroenteropancreatic (GEP) neuroendocrine tumors; …

Background Brain metastases (BM) are frequently observed in advanced renal-cell
carcinoma (RCC). Historically these individuals have been excluded from clinical trials, but …